• The role of outcomes-based agreements (OBAs) in mitigating financial risk for payers and facilitating patient access to these therapies
• Real-world evidence on the durability of responses and long-term safety profiles of CAR-T therapies
• The implications of these outcomes for future access, pricing, and reimbursement decisions

This session will analyze whether these long-term outcomes justify continued access to CAR-T and cell therapies, considering both clinical results and cost-effectiveness data, and how OBAs may evolve to support sustainable access moving forward.

Sponsor: Lifescience Dynamics